Company intelligence / Profile preview

GlycoEra AG

Wädenswil, Zurich, Switzerlandglycoera.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GlycoEra AG develops first-in-class therapeutics using its proprietary CustomGlycan platform to enable targeted degradation/removal of extracellular pathogenic proteins. The company’s pipeline focuses on autoimmune, inflammatory, immuno-oncology, neurology, and infectious disease indications. All programs are currently in the preclinical stage. The company has raised significant Series A funding from leading life science investors including Bristol Myers Squibb, Roche Venture Fund, Sofinnova Partners, LimmaTech Biologics AG, and others.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Protein drugs (biologics)AntibodiesExtracellular protein degraders
Industry: Biotech

Drug pipeline

1 asset

GE8820

Preclinical

Partnerships

Bristol Myers SquibbLimmaTech Biologics AG

Beyond the preview

Go deeper on GlycoEra AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoEra AG.

Explore the full profile